GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Effective Interest Rate on Debt %

Zealand Pharma A/S (Zealand Pharma A/S) Effective Interest Rate on Debt % : 7.55% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Zealand Pharma A/S's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $2.80 Mil. Zealand Pharma A/S's average total debt for the quarter that ended in Mar. 2024 was $37.09 Mil. Therefore, Zealand Pharma A/S's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 7.55%.


Zealand Pharma A/S Effective Interest Rate on Debt % Historical Data

The historical data trend for Zealand Pharma A/S's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Effective Interest Rate on Debt % Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.74 2.78 0.88 8.80 9.04

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.42 11.10 12.02 3.01 7.55

Competitive Comparison of Zealand Pharma A/S's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Zealand Pharma A/S's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Effective Interest Rate on Debt % falls into.



Zealand Pharma A/S Effective Interest Rate on Debt % Calculation

Zealand Pharma A/S's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -3.641/( (63.146+17.445)/ 2 )
=-1  *  -3.641/40.2955
=9.04 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=61.049 + 2.097
=63.146

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=15.008 + 2.437
=17.445

Zealand Pharma A/S's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -2.8/( (17.445+56.734)/ 2 )
=-1  *  -2.8/37.0895
=7.55 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=15.008 + 2.437
=17.445

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=54.552 + 2.182
=56.734

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Zealand Pharma A/S  (OTCPK:ZLDPF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Zealand Pharma A/S Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.